Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation

scientific article published on 16 September 2016

Decreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3892/OL.2016.5147
P932PMC publication ID5104224
P698PubMed publication ID27895765

P2093author name stringChundong Yu
Simin Liu
Lin Hou
Yaqiu Wang
Jinlian Song
Linlin Han
Zhongliang Ma
Yangping Chen
P2860cites workExpression analysis of candidate breast tumour suppressor genes on chromosome 16qQ25257454
Epigenetic Changes During Cell TransformationQ27002968
Role of CHD5 in human cancers: 10 years laterQ27006929
The epigenomics of cancerQ28289975
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-upQ28306437
CHD5 is a tumor suppressor at human 1p36Q28505682
Distinct high-profile methylated genes in colorectal cancerQ33502762
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns.Q33888431
Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancerQ34334833
Molecular evidence for the bi-clonal origin of neuroendocrine tumor derived metastasesQ34467471
Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.Q34579614
DNA methylation and gene silencing in cancer: which is the guilty party?Q34770507
Mechanisms of CHD5 Inactivation in NeuroblastomasQ35836491
Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancerQ36245354
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomasQ36790715
Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancerQ36944199
Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?Q37025333
The quest for the 1p36 tumor suppressorQ37138877
Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stagesQ37626242
Breast cancer statistics, 2011Q37942073
CHD5, a tumor suppressor that is epigenetically silenced in lung cancerQ39424870
The inheritance of epigenetic defectsQ39671673
Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancerQ39951297
Rethinking TNM: breast cancer TNM classification for treatment decision-making and researchQ40351318
CHD5 is down-regulated through promoter hypermethylation in gastric cancerQ42602377
Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer DatabasesQ44438551
Prognostic Value of Breast Cancer Subtypes, Ki-67 Proliferation Index, Age, and Pathologic Tumor Characteristics on Breast Cancer Survival in Caucasian WomenQ53119241
Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancerQ71527028
Two distinct regions involved in 1p deletion in human primary breast cancerQ72217127
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibitionQ73393598
DNA methylation and cancerQ81002014
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectDNA methylationQ874745
P304page(s)4021-4026
P577publication date2016-09-16
P1433published inOncology LettersQ20640514
P1476titleDecreased expression of the CHD5 gene and its clinicopathological significance in breast cancer: Correlation with aberrant DNA methylation
P478volume12

Reverse relations

cites work (P2860)
Q92646405Expression of CHD5 may serve as an independent biomarker of prognosis in colorectal cancer via immunohistochemical staining
Q41049866Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.

Search more.